Literature DB >> 31656785

Apixaban or rivaroxaban in the treatment of acute venous thromboembolism?

Maja Hellfritzsch1, Erik L Grove2,3, Kasper Adelborg4,5.   

Abstract

Entities:  

Year:  2019        PMID： 31656785      PMCID： PMC6789368          DOI： 10.21037/atm.2019.07.03

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  18 in total

1.  Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism.

Authors:  Simon Mantha; Jack Ansell
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

2.  2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.

Authors:  Stavros V Konstantinides; Adam Torbicki; Giancarlo Agnelli; Nicolas Danchin; David Fitzmaurice; Nazzareno Galiè; J Simon R Gibbs; Menno V Huisman; Marc Humbert; Nils Kucher; Irene Lang; Mareike Lankeit; John Lekakis; Christoph Maack; Eckhard Mayer; Nicolas Meneveau; Arnaud Perrier; Piotr Pruszczyk; Lars H Rasmussen; Thomas H Schindler; Pavel Svitil; Anton Vonk Noordegraaf; Jose Luis Zamorano; Maurizio Zompatori
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

3.  Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study.

Authors:  Caroline Sindet-Pedersen; Laila Staerk; Jannik Langtved Pallisgaard; Thomas Alexander Gerds; Jeffrey S Berger; Christian Torp-Pedersen; Gunnar H Gislason; Jonas Bjerring Olesen
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2018-10-01

4.  A changing landscape: Temporal trends in incidence and characteristics of patients hospitalized with venous thromboembolism 2006-2015.

Authors:  A M Münster; T B Rasmussen; A M Falstie-Jensen; L Harboe; G Stynes; L Dybro; M L Hansen; A Brandes; E L Grove; S P Johnsen
Journal:  Thromb Res       Date:  2019-02-13       Impact factor: 3.944

5.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.

Authors:  Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores
Journal:  Chest       Date:  2016-01-07       Impact factor: 9.410

Review 6.  Deep vein thrombosis and pulmonary embolism.

Authors:  Marcello Di Nisio; Nick van Es; Harry R Büller
Journal:  Lancet       Date:  2016-06-30       Impact factor: 79.321

7.  30-year mortality after venous thromboembolism: a population-based cohort study.

Authors:  Kirstine Kobberøe Søgaard; Morten Schmidt; Lars Pedersen; Erzsébet Horváth-Puhó; Henrik Toft Sørensen
Journal:  Circulation       Date:  2014-06-26       Impact factor: 29.690

Review 8.  Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.

Authors:  A T Cohen; M Hamilton; S A Mitchell; H Phatak; X Liu; A Bird; D Tushabe; S Batson
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

9.  Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study.

Authors:  Caroline Sindet-Pedersen; Jannik Langtved Pallisgaard; Laila Staerk; Jeffrey S Berger; Morten Lamberts; Christian Torp-Pedersen; Gunnar H Gislason; Jonas Bjerring Olesen
Journal:  Sci Rep       Date:  2017-06-13       Impact factor: 4.379

10.  Anticoagulant therapies for acute venous thromboembolism: a comparison between those discharged directly from the emergency department versus hospital in two Canadian cities.

Authors:  Tammy J Bungard; Bruce Ritchie; Jennifer Bolt; William M Semchuk
Journal:  BMJ Open       Date:  2018-10-31       Impact factor: 2.692
View more
  1 in total

1.  Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies.

Authors:  Olivia Wu; Stephen Morris; Torben Bjerregaard Larsen; Flemming Skjøth; Alex Evans; Kevin Bowrin; Piotr Wojciechowski; Wojciech Margas; Maria Huelsebeck
Journal:  Cardiovasc Ther       Date:  2022-06-09       Impact factor: 3.368
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.